Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
Jasper Therapeutics (JSPR) announced an expansion of its clinical program for chronic urticaria treatments. The company is initiating an open-label extension study that will include patients from both BEACON and SPOTLIGHT studies. Additionally, Jasper received regulatory approval in the US and EU to add a 360mg single-dose cohort to the BEACON study in chronic spontaneous urticaria (CSU), with enrollment already begun.
Initial data from all doses up to 240mg in the BEACON study will be reported during the week of January 6th, 2025, while data from the new 360mg cohort is expected in the first half of 2025. The company plans to commence registrational studies in the second half of 2025.
Jasper Therapeutics (JSPR) ha annunciato un'espansione del suo programma clinico per i trattamenti dell'orticaria cronica. L'azienda sta avviando uno studio di estensione aperto che includerà pazienti provenienti sia dagli studi BEACON che SPOTLIGHT. Inoltre, Jasper ha ricevuto l'approvazione normativa negli Stati Uniti e nell'UE per aggiungere un coorte da 360 mg in dose singola allo studio BEACON sull'orticaria spontane cronica (CSU), con l'arruolamento già iniziato.
I dati iniziali da tutte le dosi fino a 240 mg nello studio BEACON saranno riportati durante la settimana del 6 gennaio 2025, mentre i dati relativi alla nuova coorte da 360 mg sono attesi nella prima metà del 2025. L'azienda prevede di avviare studi registrativi nella seconda metà del 2025.
Jasper Therapeutics (JSPR) anunció una expansión de su programa clínico para tratamientos de urticaria crónica. La compañía está iniciando un estudio de extensión de etiqueta abierta que incluirá pacientes de los estudios BEACON y SPOTLIGHT. Además, Jasper recibió la aprobación regulatoria en EE. UU. y UE para añadir una cohorte de dosis única de 360 mg al estudio BEACON en urticaria crónica espontánea (CSU), con la inscripción ya comenzada.
Los datos iniciales de todas las dosis de hasta 240 mg en el estudio BEACON se reportarán durante la semana del 6 de enero de 2025, mientras que se esperan datos de la nueva cohorte de 360 mg para la primera mitad de 2025. La compañía planea comenzar estudios de registro en la segunda mitad de 2025.
재스퍼 테라퓨틱스(JSPR)는 만성 두드러기 치료를 위한 임상 프로그램의 확대를 발표했습니다. 이 회사는 BEACON 및 SPOTLIGHT 연구에서 환자를 포함하는 공개 연장 연구를 시작할 예정입니다. 또한 재스퍼는 만성 자발성 두드러기(CSU)에 대한 BEACON 연구에 360mg 단일 용량 집단을 추가할 수 있도록 미국 및 EU에서 규제 승인을 받았으며, 등록은 이미 시작되었습니다.
BEACON 연구에서 240mg까지 모든 용량의 초기 데이터는 2025년 1월 6일 주에 보고될 예정이며, 새로운 360mg 집단의 데이터는 2025년 상반기에 예상됩니다. 이 회사는 2025년 하반기에 등록 연구를 시작할 계획입니다.
Jasper Therapeutics (JSPR) a annoncé une expansion de son programme clinique pour les traitements de l'urticaire chronique. La société va lancer une étude d'extension ouverte qui inclura des patients des études BEACON et SPOTLIGHT. De plus, Jasper a reçu l'approbation réglementaire aux États-Unis et en Europe pour ajouter une cohorte de dose unique de 360 mg à l'étude BEACON sur l'urticaire chronique spontanée (CSU), l'inscription ayant déjà commencé.
Les données initiales de toutes les doses allant jusqu'à 240 mg dans l'étude BEACON seront rapportées durant la semaine du 6 janvier 2025, tandis que les données de la nouvelle cohorte de 360 mg sont attendues pour la première moitié de 2025. La société prévoit de commencer les études d'enregistrement dans la seconde moitié de 2025.
Jasper Therapeutics (JSPR) gab eine Erweiterung seines klinischen Programms zur Behandlung von chronischer Urtikaria bekannt. Das Unternehmen startet eine offene Erweiterungsstudie, die Patienten aus den BEACON- und SPOTLIGHT-Studien einbezieht. Darüber hinaus erhielt Jasper die behördliche Genehmigung in den USA und in der EU, um eine 360 mg Einzeldosisgruppe in die BEACON-Studie zur chronischen spontanen Urtikaria (CSU) aufzunehmen, wobei die Rekrutierung bereits begonnen hat.
Die ersten Daten aller Dosen bis zu 240 mg aus der BEACON-Studie werden in der Woche des 6. Januar 2025 berichtet, während die Daten aus der neuen 360 mg Gruppe in der ersten Hälfte von 2025 erwartet werden. Das Unternehmen plant, in der zweiten Hälfte von 2025 Zulassungsstudien zu beginnen.
- Received US and EU regulatory clearance for 360mg dose expansion
- Successfully initiated enrollment in new 360mg cohort
- On track to report initial BEACON study data in January 2025
- Expanding clinical program with open-label extension study
- None.
Insights
The expansion of Jasper Therapeutics' clinical program for briquilimab represents an incremental development in their CSU pipeline. The addition of a 360mg single-dose cohort and an open-label extension study will provide valuable long-term safety and efficacy data. However, this is primarily a procedural update about ongoing trials rather than results-driven news.
The key milestone to watch remains the initial data readout from the BEACON study (up to 240mg doses) expected in January 2025, followed by 360mg cohort data in H1 2025. These future catalysts, along with planned registrational studies in H2 2025, will be more significant for assessing briquilimab's potential in the competitive CSU market.
REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow up period. Additionally, Jasper also announced it has obtained regulatory clearance in the US and in the EU to further expand the BEACON study in CSU by adding a 360mg single-dose cohort (n=4), and that enrollment in this cohort has commenced. Jasper continues to plan to report initial data from all doses of the BEACON study up through 240mg in CSU during the week of January 6th, 2025. Data from the newly added 360mg single-dose cohort is expected to be reported in the first half of 2025.
“I am very pleased with the ability of our clinical and regulatory teams to efficiently advance our clinical development plan in support of generating a robust data set in chronic urticaria,” said Ronald Martell, President and Chief Executive Officer of Jasper. “The addition of the 360mg single-dose cohort in the BEACON study in CSU will allow us to evaluate another potential loading dose leveraging the ongoing clinical trial, and the rollover extension study will allow us to gather longer-term safety and efficacy data at therapeutic doses for patients in both BEACON and SPOTLIGHT. The expanded breadth of clinical data provided in CSU and CindU should further support optimal biologic dosing in our registrational studies, planned to commence in the second half of 2025.”
About Briquilimab
Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU or with CIndU and is initiating a clinical study in patients with asthma. Briquilimab is also currently in clinical studies as a treatment for patients with LR-MDS and as a conditioning agent for cell therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU, and as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), Fanconi anemia (FA), and sickle cell disease (SCD).
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria, asthma and lower to intermediate risk MDS and as a conditioning agent for stem cell transplants for rare diseases such as SCD, FA and SCID. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU and as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertx.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; the expected number of participants in the 360mg single-dose cohort; Jasper’s expected timing for presenting initial data from all doses of the BEACON study up through the 240mg dose cohort in CSU and from the 360mg single-dose cohort; Jasper’s expectations regarding the commencement and timing of registrational studies; and Jasper’s expectation that the expanded clinical data should further support optimal biologic dosing in its registrational studies. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com
Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com
Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
FAQ
When will Jasper Therapeutics (JSPR) report initial data from the BEACON study?
What is the new dosage cohort added to JSPR's BEACON study?
When will JSPR begin its registrational studies for chronic urticaria treatments?